Tech Company Financing Transactions
Arcus Biosciences Funding Round
On 8/30/2016, Arcus Biosciences raised $120 million in funding from Celgene, Foresite Capital and Novartis Venture Fund.
Transaction Overview
Company Name
Announced On
8/30/2016
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Undisclosed
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
3928 Point Eden Way
Hayward, CA 94545
USA
Hayward, CA 94545
USA
Phone
Undisclosed
Website
Email Address
Overview
Arcus Biosciences (NYSE: RCUS) The field of immuno-oncology (or cancer immunotherapy) has exploded in the past decade. Cancer immunotherapies generally work by interfering with the inhibitory signals produced by tumors against certain elements of the immune system. Arcus is initially developing drug therapies for small molecules along the ATP-adenosine pathway.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Terry Rosen
President
Juan Jaen
Vice President
Andrew Pennell
Vice President
Jay Powers
Vice President
Ulrike Schindler
Vice President
Nigel Walker
VP - Bus. Development
Timothy Sullivan
VP - Engineering
Steve Young
Browse more venture capital transactions:
Prev: 8/30/2016: Plowz and Mowz venture capital transaction
Next: 8/30/2016: HighRoads venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs